CSL LTD SPON.ADR 2 (CSJA) - Total Assets
Based on the latest financial reports, CSL LTD SPON.ADR 2 (CSJA) holds total assets worth €38.45 Billion EUR (≈ $44.95 Billion USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CSL LTD SPON.ADR 2 - Total Assets Trend (2022–2025)
This chart illustrates how CSL LTD SPON.ADR 2's total assets have evolved over time, based on quarterly financial data. For live market cap, price, and company overview, see CSJA market cap overview.
CSL LTD SPON.ADR 2 - Asset Composition Analysis
Current Asset Composition (June 2025)
CSL LTD SPON.ADR 2's total assets of €38.45 Billion consist of 30.1% current assets and 69.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.5% |
| Accounts Receivable | €2.28 Billion | 5.8% |
| Inventory | €6.47 Billion | 16.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €8.12 Billion | 20.6% |
| Goodwill | €8.06 Billion | 20.5% |
Asset Composition Trend (2022–2025)
This chart illustrates how CSL LTD SPON.ADR 2's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CSL LTD SPON.ADR 2 (CSJA) net assets for net asset value and shareholders' equity analysis.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSL LTD SPON.ADR 2's current assets represent 30.1% of total assets in 2025, a decrease from 58.1% in 2022.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, down from 36.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 9.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 20.6% of total assets.
CSL LTD SPON.ADR 2 Competitors by Total Assets
Key competitors of CSL LTD SPON.ADR 2 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $584.09 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $45.17 Million |
CSL LTD SPON.ADR 2 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.86 | 2.18 | - |
| Quick Ratio | 0.85 | 0.97 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €5.23 Billion | €5.82 Billion | - |
CSL LTD SPON.ADR 2 - Advanced Valuation Insights
This section examines the relationship between CSL LTD SPON.ADR 2's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.29 |
| Latest Market Cap to Assets Ratio | 1.02 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | €39.40 Billion |
| Market Capitalization | $40.06 Billion USD |
Valuation Analysis
Above Book Valuation: The market values CSL LTD SPON.ADR 2's assets above their book value (1.02x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: CSL LTD SPON.ADR 2's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSL LTD SPON.ADR 2 (2022–2025)
The table below shows the annual total assets of CSL LTD SPON.ADR 2 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €39.40 Billion ≈ $46.07 Billion |
+3.63% |
| 2024-06-30 | €38.02 Billion ≈ $44.45 Billion |
+4.93% |
| 2023-06-30 | €36.23 Billion ≈ $42.36 Billion |
+27.83% |
| 2022-06-30 | €28.35 Billion ≈ $33.14 Billion |
-- |
About CSL LTD SPON.ADR 2
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more